JWH-193
JWH-193 is a drug from the aminoalkylindole family which acts as a cannabinoid receptor agonist. It was invented by the pharmaceutical company Sanofi-Winthrop in the early 1990s. JWH-193 has a binding affinity at the CB1 receptor of 6nM, binding around seven times more tightly than the parent compound JWH-200,[1] though with closer to twice the potency of JWH-200 in activity tests. A structural isomer of JWH-193 with the methyl group on the indole ring instead of the naphthoyl ring, was also found to be of similarly increased potency over JWH-200.[2][3]
See also
References
- ^ Huffman JW, Padgett LW. Recent Developments in the Medicinal Chemistry of Cannabimimetic Indoles, Pyrroles and Indenes. Current Medicinal Chemistry, 2005; 12: 1395-1411.
- ^ Eissenstat MA, Bell MR, D'Ambra TE, Alexander EJ, Daum SJ, Ackerman JH, Gruett MD, Kumar V, Estep KG, Olefirowicz EM (August 1995). "Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics". Journal of Medicinal Chemistry 38 (16): 3094–105. doi:10.1021/jm00016a013. PMID 7636873.
- ^ Shim JY, Collantes ER, Welsh WJ, Subramaniam B, Howlett AC, Eissenstat MA, Ward SJ (November 1998). "Three-dimensional quantitative structure-activity relationship study of the cannabimimetic (aminoalkyl)indoles using comparative molecular field analysis". Journal of Medicinal Chemistry 41 (23): 4521–32. doi:10.1021/jm980305c. PMID 9804691.
|
|
Plant cannabinoids |
|
|
Cannabinoid metabolites |
|
|
Endogenous cannabinoids |
|
|
Synthetic cannabinoid
receptor agonists |
Classical cannabinoids
(Dibenzopyrans)
|
|
|
Nonclassical cannabinoids
|
|
|
Benzoylindoles
|
|
|
Naphthoylindoles
|
|
|
Naphthylmethylindoles
|
JWH-175 · JWH-184 · JWH-185 · JWH-192 · JWH-194 · JWH-195 · JWH-196 · JWH-197 · JWH-199
|
|
Phenylacetylindoles
|
|
|
Naphthoylpyrroles
|
|
|
Eicosanoids
|
|
|
Others
|
|
|
|
Allosteric modulators of
cannabinoid receptors |
|
|
Endocannabinoid
activity enhancers |
|
|
Cannabinoid receptor
antagonists and
inverse agonists |
|
|